NeuroMedica

Executive Summary

NeuroMedica is a private medical device company developing The Backstop, a novel endovascular flow diverter for the minimally invasive treatment of cerebral aneurysms, specifically targeting bifurcation aneurysms—a challenging subset that accounts for approximately 50% of all aneurysm cases. The device is licensed from Cornell University and aims to address the limitations of current standards of care, which often require complex multi-device approaches or carry higher risk of complications. By providing a single-device solution, The Backstop has the potential to improve patient outcomes, reduce procedure time, and lower costs for healthcare systems. While the company has not disclosed its development stage, the technology represents a significant advance in neurointerventional therapy and could capture a substantial share of the growing cerebral aneurysm treatment market. As a private entity based in San Diego, NeuroMedica has likely secured seed or early-stage funding to advance preclinical or clinical work. The next milestones will be critical in validating the device's safety and efficacy in human trials. With a focused product strategy and strong intellectual property from Cornell, the company is well-positioned to attract strategic partnerships or additional financing as it progresses toward commercialization. However, without public disclosures on trial status or regulatory timelines, the near-term outlook remains uncertain. Successful completion of pivotal studies and FDA clearance are key value inflection points that would unlock significant market opportunity.

Upcoming Catalysts (preview)

• Q3 2026Initiation of First-in-Human Clinical Trial60% success
• Q1 2027FDA Investigational Device Exemption (IDE) Approval50% success
• Q4 2026Strategic Partnership or Licensing Deal with Major Neurovascular Company40% success